ABSTRACT
A 6-year-old neutered male mixed-breed dog underwent curative-intent surgical resection of a hard palatal multilobular osteochondrosarcoma and closure of the defect using bilateral buccal mucosal flaps. However, failure of the flaps resulted in a massive hard palatal defect that was subsequently repaired using a haired skin angularis oris axial pattern flap. This report describes the clinical outcome using this surgical approach and novel complications encountered. Key clinical message: The haired skin angularis oris axial pattern flap appears to be a suitable and robust option for reconstruction of large palatal defects.
Utilisation d'un lambeau cutanée poilus avec rotation axiale au niveau de l'artère angularis oris chez un chien pour corriger une fistule oronasale volumineuse secondaire à la résection d'un ostéochondrosarcome multilobulaire du palais dur. Un chien croisé mâle castré de 6 ans a subi une résection chirurgicale à visée curative d'un ostéochondrosarcome multilobulaire du palais dur et une fermeture de l'anomalie par des lambeaux de la muqueuse buccale. Cependant, la défaillance des lambeaux a entraîné un défaut important du palais dur qui a ensuite été réparé à l'aide d'un lambeau de peau avec poils avec rotation axiale au niveau de l'artère angularis oris. Ce rapport décrit les résultats cliniques de cette approche chirurgicale et les nouvelles complications rencontrées.Message clinique clé :L'utilisation d'un lambeau de peau avec poils avec rotation axiale au niveau de l'artère angularis oris semble être une option appropriée et robuste pour la reconstruction des défauts importants du palais.(Traduit par Dr Serge Messier).
Subject(s)
Dog Diseases , Surgical Flaps , Animals , Dogs , Male , Dog Diseases/surgery , Surgical Flaps/veterinary , Palate, Hard/surgery , Osteosarcoma/veterinary , Osteosarcoma/surgery , Bone Neoplasms/veterinary , Bone Neoplasms/surgery , Palatal Neoplasms/veterinary , Palatal Neoplasms/surgery , Oral Fistula/veterinary , Oral Fistula/surgery , Oral Fistula/etiology , Postoperative Complications/veterinary , Postoperative Complications/surgeryABSTRACT
OBJECTIVE: To describe the perioperative characteristics and outcomes in dogs that underwent transperitoneal laparoscopic ureteronephrectomy (TLU) for primary renal neoplasia. STUDY DESIGN: Short case series. ANIMALS: Seven client-owned dogs. METHODS: Medical records were reviewed and data extracted regarding perioperative characteristics and animal outcomes. TLU was performed using a single-port + 1 or multiple port techniques. Hemostatic clips or a vessel-sealing device were used for occlusion of renal hilar vessels. The ureter was occluded and transected close to the ureterovesicular junction and the tumor was placed in a specimen retrieval bag for extraction from the abdomen. RESULTS: Preoperative contrast enhanced computed tomography (CECT) was performed in 6/7 dogs. Median estimated tumor volume measured from abdominal CECT removed by TLU was 32.42 cm3 (interquartile range [IQR] 14.76-94.85). Median surgery time for TLU was 90 minutes (IQR 85-105). In one dog, elective conversion to open laparotomy was performed due to large tumor size. Median time to discharge was 31 hours (IQR 24-48). No major perioperative complications occurred and all dogs survived to discharge. Progression free survival in four dogs was 422 days (IQR 119-784). CONCLUSION: TLU was performed for the extirpation of modest sized primary renal tumors with acceptable perioperative outcomes and a low complication rate. CLINICAL RELEVANCE: TLU may be considered for the treatment of selected cases of primary renal neoplasia in dogs.
Subject(s)
Dog Diseases , Kidney Neoplasms , Laparoscopy , Nephroureterectomy , Animals , Dog Diseases/surgery , Dogs , Kidney Neoplasms/surgery , Kidney Neoplasms/veterinary , Laparoscopy/veterinary , Nephroureterectomy/veterinary , Retrospective StudiesABSTRACT
An 8-year-old, spayed female, Doberman pinscher dog was presented to the Ontario Veterinary College Health Sciences Center for evaluation of a large subcutaneous mass on the right cranial ventral abdomen. Computed tomography localized a 6 × 7 cm soft tissue mass to the site of a laparoscopic-assisted gastropexy performed 3 years earlier. Body wall resection with wide surgical margins was performed. Histological evaluation identified the mass as a grade III soft tissue sarcoma with clean surgical margins. To the authors' knowledge, this report is the first to detail a case of a soft tissue sarcoma that is suspected to have originated at and/or infiltrated into tissues that were previously incised during a surgical procedure. Key clinical message: Based on this case, there is a possibility of a clinical correlate to the feline injection site sarcoma in the canine species.
Sarcome des tissus mous au site d'une gastropexie aidée par laparoscopie antérieure chez un chien. Une chienne Doberman pinscher stérilisée âgée de 8 ans fut présentée au Health Sciences Center de l'Ontario Veterinary College pour évaluation d'une large masse sous-cutanée au niveau de l'abdomen ventral crânial droit. Une tomodensitométrie permis de localiser une masse de tissus mous de 6 × 7 cm au site d'une gastropexie aidée par laparoscopie effectuée 3 ans plus tôt. Une résection de la paroi corporelle avec de larges bordures chirurgicales fut réalisée. Une évaluation histologique identifia la masse comme étant un sarcome des tissus mous de grade III avec des bordures chirurgicales nettes. À la connaissance des auteurs ce rapport est le premier à détailler un cas de sarcome des tissus mous qui est suspecté avoir son origine et/ou avoir infiltré des tissus qui furent précédemment incisés durant une procédure chirurgicale.Message clinique clé:Sur la base de ce cas, il y a possibilité d'une relation clinique avec le sarcome du site d'injection chez le chat chez l'espèce canine.(Traduit par Dr Serge Messier).
Subject(s)
Cat Diseases , Dog Diseases , Gastropexy , Laparoscopy , Sarcoma , Animals , Cats , Dog Diseases/surgery , Dogs , Female , Gastropexy/veterinary , Laparoscopy/veterinary , Ontario , Sarcoma/surgery , Sarcoma/veterinaryABSTRACT
BACKGROUND: Evolution of indolent to aggressive lymphoma has been described in dogs but is difficult to distinguish from the de novo development of a second, clonally distinct lymphoma. Differentiation of these scenarios can be aided by next generation sequencing (NGS)-based assessment of clonality of lymphocyte antigen receptor genes. CASE PRESENTATION: An 8-year-old male intact Mastiff presented with generalized lymphadenomegaly was diagnosed with nodal T zone lymphoma (TZL) based on cytology, histopathology, immunohistochemistry and flow cytometry. Thirteen months later, the dog re-presented with progressive lymphadenomegaly, and based on cytology and flow cytometry, a large B cell lymphoma (LBCL) was diagnosed. Sequencing-based clonality testing confirmed the de novo development of a LBCL and the persistence of a TZL. CONCLUSIONS: The occurrence of two distinct lymphoid neoplasms should be considered if patient features and tumor cytomorphology or immunophenotype differ among sequential samples. Sequencing-based clonality testing may provide conclusive evidence of two concurrent and distinct clonal lymphocyte populations, termed most appropriately "composite lymphoma".
Subject(s)
Dog Diseases/pathology , Lymphoma, Large B-Cell, Diffuse/veterinary , Lymphoma, T-Cell/veterinary , Animals , Antineoplastic Agents, Alkylating/administration & dosage , Antineoplastic Agents, Alkylating/therapeutic use , Antineoplastic Agents, Hormonal/administration & dosage , Antineoplastic Agents, Hormonal/therapeutic use , Chlorambucil/administration & dosage , Chlorambucil/therapeutic use , Dogs , Lymphoma, Large B-Cell, Diffuse/complications , Lymphoma, Large B-Cell, Diffuse/pathology , Lymphoma, T-Cell/complications , Lymphoma, T-Cell/pathology , Male , Prednisone/administration & dosage , Prednisone/therapeutic useABSTRACT
BACKGROUND: Atazanavir causes plasma indirect bilirubin to increase. We evaluated associations between Gilbert's polymorphism and bilirubin-related atazanavir discontinuation stratified by race/ethnicity. PATIENTS AND METHODS: Patients had initiated atazanavir/ritonavir-containing regimens at an HIV primary care clinic in the southeastern USA, and had at least 12 months of follow-up data. Metabolizer group was defined by UGT1A1 rs887829 CâT. Genome-wide genotype data were used to adjust for genetic ancestry in combined population analyses. RESULTS: Among 321 evaluable patients, 15 (4.6%) had bilirubin-related atazanavir discontinuation within 12 months. Homozygosity for rs887829 T/T was present in 28.1% of Black, 21.4% of Hispanic, and 8.6% of White patients. Among all patients the hazard ratio (HR) for bilirubin-related discontinuation with T/T versus C/C genotype was 7.3 [95% confidence interval (CI): 1.7-31.5; P=0.007]. Among 152 White patients the HR was 14.4 (95% CI: 2.6-78.7; P=0.002), but among 153 Black patients the HR was 0.8 (95% CI: 0.05-12.7; P=0.87). CONCLUSION: Among patients who initiated atazanavir/ritonavir-containing regimens, UGT1A1 slow metabolizer genotype rs887829 T/T was associated with increased bilirubin-related discontinuation of atazanavir in White but not in Black patients, this despite T/T genotype being more frequent in Black patients.
Subject(s)
Atazanavir Sulfate/adverse effects , Glucuronosyltransferase/genetics , HIV Infections/drug therapy , HIV Infections/ethnology , HIV Protease Inhibitors/adverse effects , Jaundice/ethnology , Adult , Black or African American/genetics , Bilirubin/blood , Female , Genetic Association Studies , Genotype , HIV Infections/blood , Hispanic or Latino/genetics , Humans , Jaundice/blood , Jaundice/chemically induced , Male , Middle Aged , Pharmacogenomic Variants , Polymorphism, Single Nucleotide , White People/geneticsABSTRACT
BACKGROUND: Efavirenz frequently causes central nervous system (CNS) symptoms. We evaluated genetic associations with efavirenz discontinuation for CNS symptoms within 12 months of treatment initiation. METHODS: Patients had initiated efavirenz-containing regimens at an HIV primary care clinic in the Southeastern United States and had at least 12 months of follow-up data. Polymorphisms in CYP2B6 and CYP2A6 defined efavirenz metabolizer categories. Genome-wide genotyping enabled adjustment for population stratification. RESULTS: Among 563 evaluable patients, 99 (17.5%) discontinued efavirenz within 12 months, 29 (5.1%) for CNS symptoms. The hazard ratio (HR) for efavirenz discontinuation for CNS symptoms in slow versus extensive metabolizers was 4.9 [95% confidence interval (CI): 1.9-12.4; P=0.001]. This HR in Whites was 6.5 (95% CI: 2.3-18.8; P=0.001) and 2.6 in Blacks (95% CI: 0.5-14.1; P=0.27). Considering only slow metabolizers, the HR in Whites versus Blacks was 3.1 (95% CI: 0.9-11.0; P=0.081). The positive predictive value of slow metabolizer genotypes for efavirenz discontinuation was 27% in Whites and 11% in Blacks. CONCLUSION: Slow metabolizer genotypes were associated significantly with efavirenz discontinuation for reported CNS symptoms. This association was considerably stronger in Whites than in Blacks.
Subject(s)
Aryl Hydrocarbon Hydroxylases/genetics , Benzoxazines/adverse effects , Central Nervous System Diseases/chemically induced , Cytochrome P-450 CYP2B6/genetics , Ethnicity/genetics , Polymorphism, Single Nucleotide , Reverse Transcriptase Inhibitors/adverse effects , Steroid Hydroxylases/genetics , Adult , Alkynes , Central Nervous System Diseases/genetics , Cyclopropanes , Female , Genetic Predisposition to Disease , Genotype , Humans , Male , Middle Aged , Pharmacogenomic Testing/methods , Predictive Value of Tests , Withholding TreatmentABSTRACT
An 8-year-old, spayed female, bichon frisé dog had incidental nodules within its falciform ligament identified on routine abdominal ultrasonography. A laparoscopic-assisted technique provided both a diagnostic and a therapeutic treatment option. A histopathological diagnosis of hemangiosarcoma was made. This is the second case reporting hemangiosarcoma of the falciform fat.
Extraction assistée par laparascopie d'un hémangiosarcome du ligament falciforme chez un chien. Une chienne Bichon frisé stérilisée âgée de 8 ans avait des nodules secondaires dans le ligament falciforme qui ont été identifiés lors d'une échographie abdominale de routine. Une technique assistée par laparascopie a fourni un diagnostic et une option de traitement thérapeutique. Un diagnostic d'hémangiosarcome a été posé à l'histopathologie. Il s'agit du deuxième cas d'hémangiosarcome du gras falciforme signalé.(Traduit par Isabelle Vallières).
Subject(s)
Dog Diseases/surgery , Hemangiosarcoma/veterinary , Laparoscopy/veterinary , Ligaments/pathology , Animals , Antineoplastic Agents/therapeutic use , Dogs , Female , Hemangiosarcoma/drug therapy , Hemangiosarcoma/surgeryABSTRACT
OBJECTIVE: Genome-wide association studies have identified a large number of single nucleotide polymorphisms (SNPs) associated with a wide array of cancer sites. Several of these variants demonstrate associations with multiple cancers, suggesting pleiotropic effects and shared biological mechanisms across some cancers. We hypothesised that SNPs previously associated with other cancers may additionally be associated with colorectal cancer. In a large-scale study, we examined 171 SNPs previously associated with 18 different cancers for their associations with colorectal cancer. DESIGN: We examined 13 338 colorectal cancer cases and 40 967 controls from three consortia: Population Architecture using Genomics and Epidemiology (PAGE), Genetic Epidemiology of Colorectal Cancer (GECCO), and the Colon Cancer Family Registry (CCFR). Study-specific logistic regression results, adjusted for age, sex, principal components of genetic ancestry, and/or study specific factors (as relevant) were combined using fixed-effect meta-analyses to evaluate the association between each SNP and colorectal cancer risk. A Bonferroni-corrected p value of 2.92×10(-4) was used to determine statistical significance of the associations. RESULTS: Two correlated SNPs--rs10090154 and rs4242382--in Region 1 of chromosome 8q24, a prostate cancer susceptibility region, demonstrated statistically significant associations with colorectal cancer risk. The most significant association was observed with rs4242382 (meta-analysis OR=1.12; 95% CI 1.07 to 1.18; p=1.74×10(-5)), which also demonstrated similar associations across racial/ethnic populations and anatomical sub-sites. CONCLUSIONS: This is the first study to clearly demonstrate Region 1 of chromosome 8q24 as a susceptibility locus for colorectal cancer; thus, adding colorectal cancer to the list of cancer sites linked to this particular multicancer risk region at 8q24.
Subject(s)
Colorectal Neoplasms/genetics , Genetic Pleiotropy , Genetic Predisposition to Disease , Polymorphism, Single Nucleotide , Aged , Chromosomes, Human, Pair 8 , Female , Genetic Markers , Genome-Wide Association Study , Genotyping Techniques , Humans , Logistic Models , Male , Middle Aged , Principal Component Analysis , Registries , Risk FactorsABSTRACT
OBJECTIVES: Efavirenz is widely prescribed for HIV-1 infection, and CYP2B6 polymorphisms 516GâT and 983TâC define efavirenz slow metabolizer genotypes. To identify genetic predictors of higher plasma efavirenz concentrations beyond these two common functional alleles, we characterized associations with mid-dosing interval efavirenz concentrations in 84 HIV-infected adults, all carrying two copies of these major loss-of-function CYP2B6 alleles. METHODS: Study participants had been randomized to efavirenz-containing regimens in prospective clinical trials and had available plasma efavirenz assay data. Analyses focused on secondary metabolism pathway polymorphisms CYP2A6 -48TâG (rs28399433), UGT2B7 735AâG (rs28365062) and UGT2B7 802TâC (rs7439366). Exploratory analyses also considered 196 polymorphisms and 8 copy number variants in 41 drug metabolism/transport genes. Mid-dosing interval efavirenz concentrations at steady-state were obtained ≥8 h but <19 h post-dose. Linear regression was used to test for associations between polymorphisms and log-transformed efavirenz concentrations. RESULTS: Increased efavirenz concentrations were associated with CYP2A6 -48TâG in all subjects (Pâ=â3.8â×â10(-4)) and in Black subjects (Pâ=â0.027) and White subjects (Pâ=â0.0011) analysed separately; and with UGT2B7 735 G/G homozygosity in all subjects (Pâ=â0.006) and in Black subjects (Pâ=â0.046) and White subjects (Pâ=â0.062) analysed separately. In a multivariable model, CYP2A6 -48TâG and UGT2B7 735 G/G homozygosity remained significant (Pâ<â0.05 for each). No additional polymorphisms or copy number variants were significantly associated with efavirenz concentrations. CONCLUSIONS: Among individuals with a CYP2B6 slow metabolizer genotype, CYP2A6 and possibly UGT2B7 polymorphisms contribute to even higher efavirenz concentrations.
Subject(s)
Benzoxazines/blood , Benzoxazines/therapeutic use , Cytochrome P-450 CYP2B6/genetics , HIV Infections/drug therapy , Secondary Metabolism/drug effects , Adult , Alkynes , Anti-HIV Agents/therapeutic use , Benzoxazines/metabolism , Black People/genetics , Cyclopropanes , Cytochrome P-450 CYP2A6/genetics , Cytochrome P-450 CYP2B6 Inducers/blood , Cytochrome P-450 CYP2B6 Inducers/therapeutic use , Female , Gene Dosage , Glucuronosyltransferase/genetics , HIV Infections/blood , HIV-1/drug effects , Humans , Male , Polymorphism, Single Nucleotide , Prospective Studies , Reverse Transcriptase Inhibitors/blood , Reverse Transcriptase Inhibitors/therapeutic use , White People/geneticsABSTRACT
We describe 3 cases of cats that were presented with a sudden onset of monoparesis as a result of arterial thromboembolism without evidence of cardiovascular disease that were subsequently diagnosed with a primary pulmonary carcinoma. Arterial tumor thromboemboli due to pulmonary carcinoma should be considered as a differential diagnosis in cases of lameness or paresis in older cats. We theorize that large tumor emboli may obstruct peripheral arteries leading to acute monoparesis.
Monoparésie associée au carcinome pulmonaire félin : compte rendu de la littérature avec 3 nouveaux cas. Nous décrivons 3 cas de chats qui ont été présentés avec l'apparition soudaine de monoparésie en raison d'un thrombo-embolisme artériel sans preuve de maladie cardiovasculaire qui ont été subséquemment diagnostiqués avec un carcinome pulmonaire primaire. Les thromboembolies des tumeurs artérielles causées par le carcinome pulmonaire devraient être considérées comme un diagnostic différentiel dans les cas de boiterie ou de parésie chez les chats âgés. Nous présentons la théorie que les embolies de grosses tumeurs peuvent bloquer les artères périphériques causant une monoparésie aiguë.(Traduit par Isabelle Vallières).
Subject(s)
Cat Diseases/diagnosis , Paresis/veterinary , Pulmonary Embolism/veterinary , Animals , Carcinoma/complications , Carcinoma/veterinary , Cat Diseases/diagnostic imaging , Cats , Diagnosis, Differential , Female , Lung Neoplasms/complications , Lung Neoplasms/veterinary , Male , Paresis/diagnosis , Paresis/etiology , Pulmonary Embolism/complications , Tomography, X-Ray ComputedABSTRACT
OBJECTIVE: To report the perioperative outcome and complications in cats undergoing minimally invasive splenectomy. ANIMALS: 17 client-owned cats. METHODS: Perioperative data were collected from cats undergoing minimally invasive splenectomy from September 2010 to June 2023. Data included history, signalment, preoperative examination and diagnostic testing results, operative technique and time, perioperative outcomes, complications, hospitalization duration, histopathological diagnosis, and outcome. RESULTS: 13 spayed females and 4 neutered males were included, with a median age of 144 months (48 to 196 months). Seven cats underwent total laparoscopic splenectomy (TLS), with 1 cat requiring conversion from TLS to laparoscopic-assisted splenectomy (LAS) due to splenomegaly and an additional cat requiring conversion from TLS to open splenectomy due to uncontrollable splenic capsular hemorrhage. Ten cats underwent LAS, with 1 cat requiring conversion to open splenectomy due to splenomegaly. Additional procedures were performed in 13 cats, with the most common being liver biopsy in 10 cats. Median operative times were 50 minutes (45 to 90 minutes) for TLS and 35 minutes (25 to 80 minutes) for LAS. An intraoperative complication occurred in 1 cat. All but 1 cat survived to discharge. Median follow-up time was 234 days (18 to 1,761 days), with 15 of 16 cats confirmed alive at 30 days and 9 of 16 cats alive at 180 days postoperatively. CLINICAL RELEVANCE: Minimally invasive splenectomy in this cohort of cats was associated with short operative times and a low perioperative complication rate. Veterinary surgeons may consider minimally invasive splenectomy as an efficient and feasible technique in the treatment of splenomegaly or modestly sized splenic masses for diagnostic and therapeutic purposes in cats.
Subject(s)
Cat Diseases , Laparoscopy , Humans , Male , Female , Cats , Animals , Splenectomy/adverse effects , Splenectomy/veterinary , Splenomegaly/veterinary , Operative Time , Treatment Outcome , Spleen/pathology , Laparoscopy/adverse effects , Laparoscopy/veterinary , Laparoscopy/methods , Retrospective Studies , Cat Diseases/surgery , Cat Diseases/pathologyABSTRACT
A 6-month-old male castrated Labrador retriever was presented for coughing and forelimb lameness. Blastomyces dermatitidis was identified in cytology of sputum and synovial fluid. Repeat arthrocentesis 7 months later revealed resolution of septic arthritis. Fungal septic arthritis should be considered for cases of monoarthritis and may respond to oral itraconazole treatment.
Blastomycose carpienne intra-articulaire chez un Labrador retriever. Un Labrador retriever mâle castré âgé de 6 mois a été présenté pour une toux et une boiterie du membre antérieur. Blastomyces dermatitidis a été identifié lors d'une cytologie de l'expectoration et du liquide synovial. Une nouvelle arthrocentèse 7 mois plus tard a révélé la résolution de l'arthrite septique. L'arthrite septique fongique devrait être considérée pour les cas de mono-arthrite et elle peut réagir au traitement à l'itraconazole oral.(Traduit par Isabelle Vallières).
Subject(s)
Arthritis, Infectious/veterinary , Blastomycosis/veterinary , Carpus, Animal/microbiology , Dog Diseases/microbiology , Itraconazole/therapeutic use , Animals , Antifungal Agents/therapeutic use , Arthritis, Infectious/drug therapy , Arthritis, Infectious/microbiology , Arthritis, Infectious/pathology , Blastomyces/isolation & purification , Blastomycosis/drug therapy , Blastomycosis/microbiology , Blastomycosis/pathology , Carpus, Animal/pathology , Dog Diseases/drug therapy , Dog Diseases/pathology , Dogs , Male , Pneumonia/microbiology , Pneumonia/veterinaryABSTRACT
INTRODUCTION: Over 90% of all adolescent suicides occur in low- and middle-income countries (LMIC), yet the majority of suicide research has focused on primarily high-income countries (HIC). METHOD: Using nationally representative data on 82,494 adolescents from thirty-four LMIC, this research employed machine learning to compare the predictive effects of multiple determinants of suicidal behaviors previously identified in the literature. RESULTS: Results indicate that distinct predictors are present for suicidal ideation, suicidal planning, and suicide attempts in youth living in LMIC as well as shared predictors common to all three behaviors. CONCLUSION: These findings provide insights into the unique needs in global mental health policy and efforts within and across adolescents in LMIC.
ABSTRACT
Myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML) are primary myeloid neoplasms in dogs generally considered to have a poor outcome. In this study, we assessed toxicity, efficacy and outcome of concurrent administration of doxorubicin and cytarabine in 11 dogs with myeloid neoplasia. Bone marrow specimens were reviewed by three pathologists and classified as either MDS (n = 2), high grade MDS/early AML (MDS/AML; n = 4) or AML (n = 5). The median number of treatment cycles was 5 (range 1-9) and resolution of cytopenia was reported in 7 of 11 dogs including 2 dogs with MDS, 2 dogs with MDS/AML, and 3 dogs with AML. The median duration of remission in the seven responders was 344 days (range 109-1428) and the median overall survival for all dogs was 369 days. Adverse events consisted of predominantly low-grade gastrointestinal illness and myelosuppression. Three dogs developed grade V toxicity manifesting with heart failure (n = 2) at 369 and 1170 days after diagnosis and acute gastrointestinal side effects (n =1). Despite a limited sample size, these results suggest that a doxorubicin and cytarabine protocol may be considered as a therapeutic option in dogs with myeloid neoplasia. Protocol safety, in particular regarding myocardial toxicity, and efficacy should be further investigated.
Subject(s)
Dog Diseases , Leukemia, Myeloid, Acute , Myelodysplastic Syndromes , Dogs , Animals , Cytarabine/therapeutic use , Dog Diseases/chemically induced , Leukemia, Myeloid, Acute/drug therapy , Leukemia, Myeloid, Acute/veterinary , Myelodysplastic Syndromes/drug therapy , Myelodysplastic Syndromes/veterinary , Doxorubicin/adverse effects , Antineoplastic Combined Chemotherapy Protocols/adverse effectsABSTRACT
OBJECTIVE: To report perioperative characteristics and outcome following bilateral, single-session, laparoscopic adrenalectomy (BSSLA) in dogs. ANIMALS: Client-owned dogs (n = 6). CLINICAL PRESENTATION AND PROCEDURES: Medical records were reviewed and perioperative data collected, including preoperative diagnostic imaging, operative details, complications, and need for conversion to open laparotomy. Bilateral, single-session, laparoscopic adrenalectomy was performed on the right or left side with a standard 3- or 4-portal transperitoneal technique. The dog was repositioned to contralateral recumbency, and laparoscopic adrenalectomy was repeated. Follow-up information was collected by telephone interviews with the owners and/or referring veterinarian. RESULTS: Median age and weight of dogs were 126 months and 14.75 kg, respectively. Contrast-enhanced CT (CECT) was performed in all dogs. Median maximal tumor diameter was 2.6 and 2.3 cm for the right and left-sided tumors, respectively. Median surgical and anesthesia times were 158 and 240 minutes, respectively. Conversion to open laparotomy was performed in 1 dog following renal vein laceration during initial adrenalectomy. Left adrenalectomy and ureteronephrectomy were performed, and the right adrenal tumor was left in situ. Cardiac arrest occurred in 1 dog following initial adrenalectomy (left); however, the dog was resuscitated successfully, and contralateral laparoscopic adrenalectomy was performed without complication. All dogs survived to hospital discharge. Follow-up ranged from 60 to 730 days (median, 264 days) for dogs that successfully underwent BSSLA. CLINICAL RELEVANCE: BSSLA was associated with favorable outcomes in this cohort of dogs. Laparoscopy may be considered in dogs with bilateral, modestly sized, noninvasive adrenal tumors.
Subject(s)
Adrenal Gland Neoplasms , Dog Diseases , Laparoscopy , Dogs , Animals , Adrenalectomy/veterinary , Adrenalectomy/methods , Retrospective Studies , Laparoscopy/veterinary , Laparoscopy/methods , Adrenal Gland Neoplasms/surgery , Adrenal Gland Neoplasms/veterinary , Laparotomy/veterinary , Dog Diseases/surgeryABSTRACT
OBJECTIVE: In a previous analysis involving protocol ANRS 12154, interindividual variability in steady-state nevirapine clearance among HIV-infected Cambodians was partially explained by CYP2B6 516GâT (CYP2B6*6). Here, we examine whether additional genetic variants predict nevirapine clearance in this cohort. METHODS: Analyses included Phnom Penh ESTHER (Ensemble pour une Solidarité Thérapeutique Hospitalière en Réseau) cohort participants who had consented for genetic testing. All participants were receiving nevirapine plus two nucleoside analogs. The mean individual nevirapine clearance estimates were derived from a population model developed on nevirapine concentrations at 18 and 36 months of therapy. Polymorphisms were assayed in ABCB1, CYP2A6, CYP2B6, CYP2C19, CYP3A4, CYP3A5, and NR1I2. RESULTS: Of 198 assayed loci, 130 were polymorphic. Among 129 individuals with evaluable genetic data, nevirapine clearance ranged from 1.06 to 5.00 l/h in 128 individuals and was 7.81 l/h in one individual. In bivariate linear regression, CYP2B6 516GâT (CYP2B6*6) was associated with lower nevirapine clearances (P=3.5×10). In a multivariate linear regression model conditioned on CYP2B6 516GâT, independent associations were identified with CYP2B6 rs7251950, CYP2B6 rs2279343, and CYP3A4 rs2687116. The CYP3A4 association disappeared after censoring the outlier clearance value. A model that included CYP2B6 516GâT (P=1.0×10), rs7251950 (P=4.8×10), and rs2279343 (P=7.1×10) explained 11% of interindividual variability in nevirapine clearance. CONCLUSION: Among HIV-infected Cambodians, several CYP2B6 polymorphisms were associated independently with steady-state nevirapine clearance. The prediction of nevirapine clearance was improved by considering several polymorphisms in combination.
Subject(s)
Anti-HIV Agents/pharmacokinetics , Asian People , Genetic Variation , HIV Infections/drug therapy , Nevirapine/pharmacokinetics , Adult , Anti-HIV Agents/therapeutic use , Cohort Studies , Female , Genotype , HIV Infections/genetics , Humans , Linear Models , Male , Middle Aged , Nevirapine/therapeutic use , Polymorphism, Single NucleotideABSTRACT
OBJECTIVE: Tacrolimus, an immunosuppressive drug widely prescribed in kidney transplantation, requires therapeutic drug monitoring due to its marked interindividual pharmacokinetic variability and narrow therapeutic index. Previous studies have established that CYP3A5 rs776746 is associated with tacrolimus clearance, blood concentration, and dose requirement. The importance of other drug absorption, distribution, metabolism, and elimination (ADME) gene variants has not been well characterized. METHODS: We used novel DNA biobank and electronic medical record resources to identify ADME variants associated with tacrolimus dose requirement. Broad ADME genotyping was performed on 446 kidney transplant recipients, who had been dosed to a steady state with tacrolimus. The cohort was obtained from Vanderbilt's DNA biobank, BioVU, which contains linked deidentified electronic medical record data. Genotyping included Affymetrix drug-metabolizing enzymes and transporters Plus (1936 polymorphisms), custom Sequenom Massarray iPLEX Gold assay (95 polymorphisms), and ancestry-informative markers. The primary outcome was tacrolimus dose requirement defined as blood concentration to dose ratio. RESULTS: In analyses, which adjusted for race and other clinical factors, we replicated the association of tacrolimus blood concentration to dose ratio with CYP3A5 rs776746 (P=7.15×10), and identified associations with nine variants in linkage disequilibrium with rs776746, including eight CYP3A4 variants. No NR1I2 variants were significantly associated. Age, weight, and hemoglobin were also significantly associated with the outcome. In final models, rs776746 explained 39% of variability in dose requirement and 46% was explained by the model containing clinical covariates. CONCLUSION: This study highlights the utility of DNA biobanks and electronic medical records for tacrolimus pharmacogenomic research.
Subject(s)
Cytochrome P-450 CYP3A/genetics , Electronic Health Records , Immunosuppressive Agents/pharmacokinetics , Kidney Transplantation/immunology , Tacrolimus/pharmacokinetics , ATP Binding Cassette Transporter, Subfamily B , ATP Binding Cassette Transporter, Subfamily B, Member 1/genetics , Adult , Age Factors , Body Weight/genetics , Databases, Nucleic Acid , Dose-Response Relationship, Drug , Drug Monitoring , Female , Genetic Association Studies , Genotype , Hemoglobins/genetics , Humans , Immunosuppressive Agents/administration & dosage , Immunosuppressive Agents/blood , Linkage Disequilibrium , Male , Middle Aged , Polymorphism, Single Nucleotide/genetics , Pregnane X Receptor , Receptors, Steroid/genetics , Tacrolimus/administration & dosage , Tacrolimus/bloodABSTRACT
Alzheimer's disease (AD) is the most common type of dementia in elderly people. Senile plaques, a pathologic hallmark of AD, are composed of amyloid ß peptide (Aß). Aß aggregation produces toxic oligomers and fibrils, causing neuronal dysfunction and memory loss. Aß is generated from two sequential proteolytic cleavages of a membrane protein, amyloid precursor protein (APP), by ß- and γ-secretases. The transmembrane (TM) domain of APP, APPTM, is the substrate of γ-secretase for Aß production. The interaction between APPTM and γ-secretase determines the production of different species of Aß. Although numerous experimental and theoretical studies of APPTM structure exist, experimental 3D structure of APPTM has not been obtained at atomic resolution. Using the pETM41 vector, we successfully expressed an MBP-APPTM fusion protein. By combining Ni-NTA chromatography, TEV protease cleavage, and reverse phase HPLC (RP-HPLC), we purified isotopically-labeled APPTM for NMR studies. The reconstitution of APPTM into micelles yielded high quality 2D (15)N-(1)H HSQC spectra. This reliable method for APPTM expression and purification lays a good foundation for future structural studies of APPTM using NMR.
Subject(s)
Amyloid beta-Protein Precursor/chemistry , Recombinant Proteins/chemistry , Amyloid beta-Protein Precursor/biosynthesis , Amyloid beta-Protein Precursor/isolation & purification , Amyloid beta-Protein Precursor/metabolism , Chromatography, Affinity , Chromatography, High Pressure Liquid , Electrophoresis, Polyacrylamide Gel , Humans , Mass Spectrometry , Micelles , Nitrogen Isotopes , Nuclear Magnetic Resonance, Biomolecular , Phosphorylcholine/analogs & derivatives , Protein Conformation , Protein Structure, Tertiary , Recombinant Proteins/biosynthesis , Recombinant Proteins/isolation & purification , Recombinant Proteins/metabolism , Reproducibility of ResultsABSTRACT
Primary pulmonary histiocytic sarcoma (PHS) is a rare form of dendritic cell or macrophage neoplasia originating within the pulmonary parenchyma. There is limited literature describing prognosis in dogs with PHS receiving curative-intent treatment consisting of surgical excision and adjuvant chemotherapy. The primary objective of this study was to report outcomes in dogs with localized PHS treated with standardized local and systemic therapy. A secondary objective was to identify prognostic factors in this population. A multi-institutional retrospective study was performed and medical records including all surgical and histopathologic reports were retrospectively reviewed. For inclusion, dogs were required to have confirmed localized PHS and they must have undergone curative-intent surgery with resection of all gross primary tumour and enlarged tracheobronchial lymph nodes; additionally, they must have received curative-intent treatment with adjuvant single-agent CCNU chemotherapy. Twenty-seven dogs from six veterinary teaching hospitals and five private practices treated from 2008-2019 were included. The overall median survival time was 432 days. Higher CCNU dose was demonstrated to have a negative impact on survival on univariate, but not multivariable, analysis. Factors that were not found to be associated with survival on univariate analysis included body weight, breed, clinical signs at the time of diagnosis, hypoalbuminaemia, tumour size, lung lobe affected, lymph node metastasis, surgical margins and CCNU dose reductions. This study supports a favourable prognosis for dogs diagnosed with localized PHS treated with curative-intent surgery in addition to adjuvant CCNU chemotherapy and suggests that multimodal treatment may be advisable to attempt to prolong survival.
Subject(s)
Dog Diseases , Histiocytic Sarcoma , Lung Neoplasms , Animals , Dog Diseases/drug therapy , Dog Diseases/pathology , Dogs , Histiocytic Sarcoma/drug therapy , Histiocytic Sarcoma/veterinary , Lomustine/therapeutic use , Lung/pathology , Lung Neoplasms/drug therapy , Lung Neoplasms/veterinary , Retrospective Studies , Treatment OutcomeABSTRACT
Cancer is the leading cause of death in dogs, yet there are no established screening paradigms for early detection. Liquid biopsy methods that interrogate cancer-derived genomic alterations in cell-free DNA in blood are being adopted for multi-cancer early detection in human medicine and are now available for veterinary use. The CANcer Detection in Dogs (CANDiD) study is an international, multi-center clinical study designed to validate the performance of a novel multi-cancer early detection "liquid biopsy" test developed for noninvasive detection and characterization of cancer in dogs using next-generation sequencing (NGS) of blood-derived DNA; study results are reported here. In total, 1,358 cancer-diagnosed and presumably cancer-free dogs were enrolled in the study, representing the range of breeds, weights, ages, and cancer types seen in routine clinical practice; 1,100 subjects met inclusion criteria for analysis and were used in the validation of the test. Overall, the liquid biopsy test demonstrated a 54.7% (95% CI: 49.3-60.0%) sensitivity and a 98.5% (95% CI: 97.0-99.3%) specificity. For three of the most aggressive canine cancers (lymphoma, hemangiosarcoma, osteosarcoma), the detection rate was 85.4% (95% CI: 78.4-90.9%); and for eight of the most common canine cancers (lymphoma, hemangiosarcoma, osteosarcoma, soft tissue sarcoma, mast cell tumor, mammary gland carcinoma, anal sac adenocarcinoma, malignant melanoma), the detection rate was 61.9% (95% CI: 55.3-68.1%). The test detected cancer signal in patients representing 30 distinct cancer types and provided a Cancer Signal Origin prediction for a subset of patients with hematological malignancies. Furthermore, the test accurately detected cancer signal in four presumably cancer-free subjects before the onset of clinical signs, further supporting the utility of liquid biopsy as an early detection test. Taken together, these findings demonstrate that NGS-based liquid biopsy can offer a novel option for noninvasive multi-cancer detection in dogs.